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A growing body of clinical and epidemiological evidence suggests that low dietary intake and/or tissue levels of n-3 (omega-3)
polyunsaturated fatty acids (PUFAs) are associated with postpartum depression. Low tissue levels of n-3 PUFAs, particularly
docosahexaenoic acid (DHA), are reported in patients with either postpartum or nonpuerperal depression. Moreover, the
physiological demands of pregnancy and lactation put childbearing women at particular risk of experiencing a loss of DHA from
tissuesincludingthebrain,especiallyinindividualswithinadequatedietaryn-3PUFAintakeorsuboptimalmetaboliccapabilities.
Animal studies indicate that decreased brain DHA in postpartum females leads to several depression-associated neurobiological
changes including decreased hippocampal brain-derived neurotrophic factor and augmented hypothalamic-pituitary-adrenal
responses to stress. Taken together, these ﬁndings support a role for decreased brain n-3 PUFAs in the multifactorial etiology
of depression, particularly postpartum depression. These ﬁndings, and their implications for research and clinical practice, are
discussed.
1.Introduction
Postpartum depression is a potentially devastating disorder
that occurs in 10%–20% of childbearing women [1–3].
The etiology remains to be fully elucidated; however, it is
complex, most likely heterogeneous, and probably involves
the interaction of environmental factors and genetic pre-
dispositions, with pregnancy or childbirth as the triggering
event [4–10]. Hormonal changes during pregnancy and after
childbirth appear to play a contributory role, but cannot
fully explain incidence of the disorder [11–13]. Untreated,
postpartum depression can lead to recurrent depressive
episodes, negatively aﬀect the development of the infant, and
in severe instances, lead to maternal suicide or infanticide
[14–16]. There is thus a critical need to elucidate causes
and risk factors of this disorder that aﬀects the health and
well-being of both mothers and infants in order to identify
means of prevention or treatment. A growing body of
evidencesuggeststhatn-3polyunsaturatedfattyacid(PUFA)
status may contribute to the development of postpartum
depression. That literature, and its implications for research
and clinical practice, is reviewed here.
2. Methods
This paper is based on literature found in PubMed searched
from 1964 through July 31, 2010. Primary outcomes of
interest were the eﬀects of pregnancy and lactation on
maternal n-3 PUFA status in humans and in animals,
relationships between n-3 PUFA status and postpartum
depression, as well as clinical trials of n-3 PUFAs in postpar-
tumdepression. Secondaryclinicaloutcomesof interestwere
relationships between n-3 PUFA status and non-puerperal
depression, and clinical trials of n-3 PUFAs in non-puerperal
depression. Preclinical outcomes of interest were the eﬀects
of manipulations of dietary or tissue n-3 PUFA status on
neurobiological systems known to be altered in depression
(i.e., hippocampal expression of brain-derived neurotrophic
factor, the hypothalamic-pituitary-adrenal axis, the CNS
serotonin and dopamine systems, and neuroinﬂammation).2 Depression Research and Treatment
Eﬀects of altered n-3 PUFA status in animal models of
depression were also examined.
3.N-3PolyunsaturatedFattyAcids
Long-chainpolyunsaturatedfattyacids(LC-PUFAs)arefatty
acids that are 20 or more carbons in length and contain
multiple double bonds. The n-3 and n-6 (or omega-3
and omega-6) families of PUFAs are synthesized from the
nutritionally essential fatty acids, α-linolenic acid (18:3n-
3; which indicates the number of carbons: the number of
double bonds, and the fatty acid family) and linoleic acid
(18:2n-6) (Figure 1). Biologically important LC-PUFAs such
as docosahexaenoic acid (DHA; 22:6n-3) and arachidonic
acid (20:4n-6) can either be synthesized from the essential
fatty acids or consumed directly in the diet from sources
such as fatty ﬁsh, which is notably rich in n-3 LC-PUFAs,
and other animal products. However, humans are relatively
ineﬃcient in synthesizing LC-PUFAs (≤6% conversion)
from the essential fatty acids [17, 18], which may be further
exacerbated by genetic polymorphisms that render certain
individuals particularly poor at synthesizing or utilizing LC-
PUFAs [19, 20]. Compounding this metabolic ineﬃciency,
diets in North America are notably low in n-3 PUFAs, partic-
ularly relative to n-6 PUFAs, which compete for metabolism
into LC-PUFAs [21]. Thus, there is considerable potential
for variation in n-3 PUFA status between populations and
between individuals within a given population.
LC-PUFAs are components of the phospholipids that
form cell membranes. The phospholipids in brain have
notably high concentrations of LC-PUFAs, with DHA being
the most abundant species. Variation in fatty acid com-
position of the phospholipids alters the physicochemical
properties of the membrane and can thus alter the function
of membrane-bound proteins and lipid rafts [22, 23]. DHA
andother LC-PUFAscanalsobe cleaved fromthe membrane
by phospholipases to serve as precursors for inter- and
intracellular signaling molecules such as prostaglandins,
neuroprotectin D1, and resolvins [22, 24–26]. In addition,
LC-PUFAs are agonists at nuclear receptors, such as the
retinoid X receptor (RXR) and peroxisome proliferator-
activated receptors (PPAR), which modulate gene expression
[27, 28]. Thus, changes in the relative abundance of speciﬁc
LC-PUFAs, particularly DHA, can aﬀect neuronal function
through a variety of mechanisms.
MostoftheDHAinthehumanbrainaccumulatesduring
the third trimester of gestation, and continues through
the ﬁrst few years of life [29–31]. DHA is supplied by
the mother to the fetus in utero, and to the neonate in
breast milk which contains high concentrations of DHA,
though concentrations vary depending on maternal diet
and other factors [32, 33]. Low availability of DHA results
in increased incorporation of docosapentaenoic acid (n-6
DPA, 22:5n-6), the 22-carbon member of the n-6 PUFA
family, thus altering the fatty acid composition of the
phospholipids [34]. This change in the composition of brain
phospholipids does not aﬀect brain weight or overall growth
[35]butisassociatedwithsuboptimalvisual,attentional,and
intellectual development [36–39].
4. Effects of Pregnancy andLactation on
MaternalN-3 PUFA Status
Asthesourceofnutritionforthedevelopingfetusandinfant,
there is considerable demand on pregnant and nursing
women to supply DHA to their oﬀspring [37, 38]. Without
an adequate diet, mothers can become depleted of nutrients.
The majority of studies reported that maternal plasma DHA
levels were decreased by as much as 50% in some individuals
after a single pregnancy, and were not fully replenished
at 26 weeks postpartum [40–44]. Additional pregnancies
resulted in further reduction of maternal DHA levels in
plasma and breast milk [43, 45]. Similar decreases in the
percentage of DHA in erythrocytes and liver have also been
reported after pregnancy and lactation in rats [46]. Although
brain fatty acid status has not been studied in humans after
pregnancy, studies in rats indicated that the DHA content
of brain phospholipids was reduced by roughly 25% after
only a single reproductive cycle (i.e., pregnancy and lactation
through weaning) if the animals were fed a diet low in n-
3 PUFAs [47, 48]. The percentage of DHA in rat brain
was not further decreased after multiple reproductive cycles;
however, a second reproductive cycle resulted in additional
incorporation of n-6 DPA [48]. While these reproduction-
associated changes in brain fatty acid composition can be
reversed by subsequent treatment with DHA (Figure 2), it is
not yet known whether this restoration of brain fatty acid
composition reverses the neurobiological changes that result
from the loss of DHA (see below).
5. N-3 PUFAs inDepression
5.1.PostpartumDepression. Epidemiologicandclinicalstud-
ies suggest that pregnancy-associated changes in n-3 LC-
PUFA status contribute to the development of postpartum
depression. A cross-national analysis indicated that higher
ﬁsh consumption, which was reﬂected in higher concen-
trations of DHA in breast milk, correlated with a lower
incidence of postpartum depression [50]. Low intake of
ﬁsh and other sources of n-3 PUFAs was also associated
with depression during pregnancy [51, 52]. Brain fatty acid
composition in postpartum depression has not been studied.
Nonetheless, in studies of plasma or serum, DHA concen-
trations, or the DHA:n-6 DPA ratio, was signiﬁcantly lower
in postpartum women experiencing depressive symptoms
than those who were not [53, 54]. Similarly, women who
later developed postpartum depression had lower serum
DHA levels after delivery than those who did not develop
depressive symptoms [55], although other studies did not
ﬁnd such a relationship [56–58]. Likewise, risk of post-
partum depression was associated with a single-nucleotide
polymorphismintheFADS1/FADS2genecluster[59],which
encodes the rate-limiting enzymes in LC-PUFA biosynthesis,
and was associated with lower proportions of DHA in breast
milk even if the women were consuming ﬁsh or ﬁsh oil
[60]. In addition, women with more than one child or who
hadshortinterpregnancyintervals(<24months)werefound
to be at higher risk of developing postpartum depressionDepression Research and Treatment 3
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Figure 1: Biosynthesis of n-3 and n-6 polyunsaturated fatty acids. The essential fatty acids α-linolenic acid and linoleic acid are metabolized
by elongases and desaturases into a variety of n-3 and n-6 LC-PUFA, respectively.
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Figure 2: Eﬀects of dietary remediation on brain phospho-
lipid DHA and n-6 DPA contents in postpartum dams with a
reproduction-anddiet-relateddecreaseinbrainDHA.Adultfemale
rats underwent two complete reproductive cycles (pregnancy and
lactation) while fed an n-3 PUFA-deﬁcient diet as previously
described [49]. At the time of weaning of the second litter, dams
were placed on a remediation diet containing DHA (4% of fat by
weight).Virgincontrolswereage-matchedfemalesfedacontroldiet
for 12 weeks. n = 6/group. Data are presented as the mean ± SEM.
∗P<. 05 versus virgin control by ANOVA and Tukey’s test.
[9, 61], consistent with the potential for greater alterations
in n-3 LC-PUFA status after multiple pregnancies and/or
inadequate time for replenishment between pregnancies.
5.2. Nonpuerperal Depression. Low n-3 PUFA status, partic-
ularly low DHA, has also been reported in non-puerperal
depression. Analyses of dietary n-3 PUFA intake indicate an
association of low n-3 PUFA consumption with depressive
symptoms [62–66]. Likewise, in postmortem studies, tissue
DHA content of the orbitofrontal cortex was decreased 22%
in individuals with major depressive disorder compared to
controls and was the only fatty acid found to be altered [67].
Similarly, the DHA content of the cingulate cortex was lower
in individuals with major depression, but was one of several
fatty acids found to be altered [68]. Studies of erythrocyte,
serum, plasma, or adipose tissue levels of DHA and other
n-3 PUFAs have found similar results [69–79]; ﬁndings
that have been supported by subsequent meta-analysis [80].
Interestingly, some studies found stronger associations of
low n-3 PUFA status in women than in men, or found an
association only in women [67, 81, 82], in whom depression
occurs with roughly twice the frequency as men [83–85].
Expression of FADS1 and several other genes involved in
lipid metabolism was also decreased in individuals who
completed suicide [86]; however, no alterations in any of the
n-3 PUFAs were found in postmortem brains from suicide
completers, even in those individuals with a diagnosis of
major depression [87, 88].
6. ClinicalTrialswithN-3 PUFAs inDepression
Clinical trials with n-3 PUFAs in depression have yielded
varying results. These diﬀerences in outcomes are likely due
to the considerable variation in the n-3 PUFA preparations
u s e d ,a sw e l la sn u m e r o u so t h e rd i ﬀerences between the
studies including the dose, duration of treatment, severity
of the depressive symptoms, and inclusion/exclusion criteria,
percentage of male and female subjects, choice of placebo,
and the inclusion of other concomitant treatments such
as psychotherapy. In addition, the populations studied in
these clinical trials also varied in their dietary n-3 and n-
6 PUFA content, which may also have contributed to the
variable outcomes. Moreover, several of the studies likely
lacked adequate statistical power.4 Depression Research and Treatment
6.1. Postpartum Depression. O n l yaf e ws t u d i e sh a v ee x a m -
ined the eﬀects of n-3 PUFA treatment speciﬁcally in post-
partum depression. Treatment with a preparation containing
DHA and eicosapentaenoic acid (EPA, 20:5n-3) (EPAX
550 [EPA:DHA, 1.5:1] 0.5, 1.4, or 2.8g/day) for 8 weeks
reduced depressive symptoms in postpartum depression
in a dose-ranging pilot study that did not include a
placebo control group [89]. In a double-blind, placebo-
controlled trial, however, treatment with DHA and EPA
(0.8 and 1.1g/day, resp.) for 8 weeks was of no additional
beneﬁt in women with perinatal major depression when
all subjects received concomitant psychotherapy [90]. Fish
oil (2960mg/day [EPA:DPA, 1.4:1] from week 34–36 of
pregnancy through 12 weeks postpartum) [91] or DHA
supplements (200mg/day for 4 months after delivery [92]o r
220mg/day from week 16 of pregnancy through 3 months
postpartum [93]) also failed to prevent the development of
postpartum depressive symptoms [91–93].
6.2. Nonpuerperal Depression. The eﬀects of n-3 PUFAs
in non-puerperal depression have been more extensively
tested (Table 1). Double-blind, placebo-controlled clinical
trials in depressed patients found that various n-3 LC-
PUFA preparations, such as EPA, a combination of EPA
and DHA, or ﬁsh oil, were beneﬁcial as an adjunct to
the patients’ current antidepressant medication [94–96]o r
when administered as monotherapy [97–100], for at least
some doses or in certain subsets of subjects. Similarly, ﬁsh
oil improved depressive symptoms in depressed Parkinson’s
patients[101].Inotherstudiesthatdidnotincludeaplacebo
control, ethyl-EPA had equal eﬃcacy to ﬂuoxetine, and the
combination of ethyl-EPA and ﬂuoxetine produced greater
improvement than ﬂuoxetine alone [102]. Some doses of
DHA alone also improved depressive symptoms in a dose-
ranging study [103]. On the other hand, other double-blind,
controlled clinical trials using DHA alone, combinations
of DHA and EPA, or ﬁsh oil found no antidepressant
eﬀects [104–106], and EPA produced no beneﬁcial eﬀects
alone or as an add-on to antidepressant medication [107–
109]. Despite the negative results of some trials, subsequent
meta-analyses and other post hoc evaluations generally sup-
port the antidepressant eﬃcacy of n-3 PUFAs, particularly
EPA, though the eﬃcacy of DHA remains unclear [110–
114]. These analyses also highlight the need for additional
controlled randomized trials with larger sample sizes and
adequate doses and treatment durations.
7. Biological Mechanismsfor N-3 PUFAs in
PostpartumDepression
Experimental studies in animals and correlational studies
in humans indicate several biological mechanisms by which
variation in n-3 PUFA consumption and/or tissue n-3 PUFA
status may contribute to the pathogenesis of depression. The
vast majority of animal studies have used diets to modulate
the availability of speciﬁc LC-PUFAs, and thus, tissue fatty
acid compositions. On the other hand, altered brain LC-
PUFAsinhumansmayresultfromgeneticvariationinPUFA
metabolism or utilization, perhaps also in combination with
inadequate diet. Nevertheless, the eﬀects of altered brain
LC-PUFA composition should likely be similar regardless
of the underlying cause. However, the neurobiological
consequences of variation in n-3 PUFA status do vary
depending on the magnitude of the change, the point in
the lifespan at which the manipulation occurred, and in
some instances, the physiological state (e.g., postpartum).
Accordingly, the eﬀects of variation in brain n-3 PUFA status
on neurobiological parameters known to be of importance
i nd e p r e s s i o na r er e v i e w e dh e r ew i t haf o c u so nt h ee ﬀects in
postpartum females.
7.1. Eﬀects on Hippocampal Expression of Brain-Derived Neu-
rotrophic Factor (BDNF). Decreased expression of BDNF in
thehippocampus,acomponentofthelimbicsysteminvolved
in memory, aﬀect, and regulation of the hypothalamic-
pituitary-adrenal axis [115], is strongly implicated in the
pathophysiology of depression. Of note, hippocampal BDNF
levels were decreased in suicide completers [116, 117]. This
decrease in BDNF expression results in decreased hippocam-
pal neurogenesis [118], and may consequently contribute
to the hippocampal atrophy observed in depression [119].
Furthermore, BDNF levels were higher in postmortem
hippocampus of antidepressant-treated patients than in
untreated patients, suggesting a role for BDNF in the
mechanism of antidepressants [120]. Similar eﬀects have
been observed in animal studies with various models of
depression, stress paradigms, and antidepressant treatments
[121–127].
When examined at the time of weaning a litter, which
is at the end of the period of greatest oﬀspring demand
for DHA in rodents [128], and thus roughly comparable
to the postpartum period in humans, female rats that
experienced a decrease in brain DHA as a result of pregnancy
and lactation while being fed an n-3 PUFA-deﬁcient diet
exhibited decreased hippocampal BDNF mRNA and peptide
levels [49]. These animals had a decrease in brain DHA
content of about 25% which is similar to the decrease
observed in postmortem brain samples from individuals
with major depressive disorder [67]. Furthermore, the mag-
nitude of the decrease in BDNF mRNA (−32%) was similar
t ot h a to b s e r v e di ns u i c i d ev i c t i m s[ 116, 117]. A decrease in
hippocampalBDNFmRNAlevelswasalsoobservedinvirgin
female rats that were fed an n-3 PUFA-deﬁcient diet for a
suﬃcient period of time (6 months) to decrease brain DHA
contentbyabout25%[49].TheseeﬀectsonBDNFcouldnot
be attributed to diﬀerences in general health, weight gain,
maternal oﬀspring burden, or serum estradiol levels [49,
129]. This suggests that the decrease in hippocampal BDNF
expression is related to brain DHA status speciﬁcally, not
an interaction of brain DHA level and reproductive status.
Even so, this eﬀect was somewhat greater in parous females
[49], suggesting that there may be some augmentation in the
postpartum state.
Findings in other animal models and in humans
also indicate a role for n-3 PUFAs in the regulation of
hippocampal BDNF expression and function. Notably, aDepression Research and Treatment 5
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DHA-enricheddietinratsincreasedhippocampalexpression
of BDNF and also increased concentrations of molecules
involved in BDNF signaling such as calmodulin kinase II and
activated Akt [130]. Similarly, an increase in hippocampal
BDNF was observed in adult mice treated with α-linoleic
acid injections [131]. Consistent with this observation, mice
or rats fed diets enriched in n-3 PUFAs had increased
expression of hippocampal BDNF and either increased
hippocampal neurogenesis or hippocampal volume [132,
133]. Likewise, in humans, higher consumption of n-3 LC-
PUFAs was associated with increased gray matter volume in
hippocampus and other corticolimbic structures, indicating
maintenance of cells in those brain regions [134]. Thus,
these data suggest that n-3 PUFAs support expression of hip-
pocampal BDNF, which in turn fosters optimal hippocampal
function.
7.2. Eﬀects on the Hypothalamic-Pituitary-Adrenal Axis.
Dysregulation of the hypothalamic-pituitary-adrenal axis is
another major clinical ﬁnding in depression [135]. These
ﬁndings include elevated basal levels of serum cortisol,
increased corticotrophin-releasing factor in cerebral spinal
ﬂuid [136–138], and disruption of negative feedback mecha-
nisms [139].
In postpartum rats with decreased brain DHA levels,
stress-induced corticosterone secretion was higher than in
postpartum rats with normal brain DHA levels [49]. In
addition, both postpartum and virgin female rats with
decreased brain DHA exhibited greater relative increases in
corticosterone secretion over baseline when subjected to an
intense stressor [49], although stressed corticosterone levels
were not diﬀerent between virgin females with decreased
brain DHA and virgin females with normal brain DHA.
This suggests that a loss of DHA from the adult brain
contributes to dysregulation of the hypothalamic-pituitary-
adrenal axis and that this eﬀect may be more pronounced in
the postpartum state.
Consistent with these ﬁndings, other animal and clinical
studies support a role for dietary and tissue n-3 PUFA status
in the modulation of the hypothalamic-pituitary-adrenal
axis. In rats, an n-3 PUFA-enriched diet resulted in lower
levels of anxiety- and stress-like behavioral eﬀects in the
elevated plus maze and the open ﬁeld test after treatment
with interleukin-1, an inﬂammatory cytokine that increases
corticosterone levels [140]. Similarly, in human studies,
ﬁsh oil supplements decreased stress responses such as
increased plasma epinephrine, norepinephrine, and cortisol,
in normal subjects [141, 142]. Furthermore, in a study of
perpetrators of domestic violence, DHA levels were inversely
related to concentrations of corticotropin-releasing factor in
cerebrospinal ﬂuid [143]. Thus, dietary and tissue n-3 PUFA
levels appear to modulate the function of the hypothalamic-
pituitary-adrenal axis in both the non-puerperal and post-
partum states, and the eﬀects of lower n-3 PUFAs are similar
to the alterations observed in depressed patients.
7.3. Eﬀects on the CNS Serotonin Systems. Decreased sero-
tonergic function plays a central role in the theories of the
pathogenesis of depression. This is supported by observa-
tions such as decreased concentrations of serotonin in the
brainstem and increased densities of serotonin receptors,
such as 5-HT1A and 5-HT2A, in the prefrontal cortex of post-
mortem depressives and suicide victims [144–150]. These
receptors downregulate after treatment with antidepressant
drugs which increase synaptic availability of serotonin [151].
Postpartum rats with decreased brain DHA levels had
increased expression of 5-HT1A receptors in the hippocam-
pus [49]. No alterations in hippocampal 5-HT1A binding
were observed in virgin females with decreased brain DHA
indicating that this represents an interaction of decreased
brain DHA content with the postpartum state. However,
this observation diﬀers from ﬁndings in depressed humans
in whom densities of hippocampal 5-HT1A receptors were
eithernotalter edorwer edecr eased[152–155].Furthermore,
the densities of 5-HT1A and 5-HT2A receptors were not
altered in the frontal cortex of either postpartum or virgin
female rats with decreased brain DHA [49]. Thus, these
ﬁndings are inconsistent with ﬁndings in humans with
non-puerperal depression. Nevertheless, the increase in
hippocampal5-HT1A receptors may represent a unique eﬀect
of a loss of brain DHA in postpartum dams that may
contribute speciﬁcally to the yet-to-be determined etiology
of postpartum depression.
Other studies in animals and humans indicate that
various aspects of the serotonin system are aﬀected by n-
3 PUFA status. In animal studies, adult female rats with a
diet-induced decrease in brain DHA content of about 25%
initiated after adulthood had decreased concentrations of
serotonin in the frontal cortex [49]. Similarly, rats fed an n-3
PUFA-deﬁcient diet from birth, which produced brain DHA
levels 61% lower than controls as a result of inadequate accu-
mulationduringpostnataldevelopment,exhibiteddecreased
midbrain expression of tryptophan hydroxylase, the enzyme
that synthesizes serotonin, and increased serotonin turnover
intheprefrontalcortex[156].Consistentwiththeseﬁndings,
piglets fed formula lacking both α-linolenic and linoleic
acids exhibited lower cortical serotonin concentrations than
those fed a formula containing the essential fatty acids [157],
further suggesting a role for brain LC-PUFA composition in
modulating serotonin levels though the speciﬁc role of n-
3 PUFAs was not addressed. In another model, rats raised
for two generations on an n-3 PUFA-deﬁcient diet, which
resulted in a 75% decrease in brain DHA content, had
increased density of 5-HT2A receptors in the frontal cortex
[158, 159]. Conversely, an n-3 PUFA-supplemented diet
reversed decreases in brain serotonin levels in mice subjected
to unpredictable chronic mild stress [160]. In humans,
low plasma DHA levels in normal subjects and alcoholics
were correlated with lower concentrations of the serotonin
metabolite 5-hydroxyindoleacetic acid in cerebrospinal ﬂuid,
a marker of altered serotonergic neurotransmission associ-
ated with depression and suicide [161, 162]. Similarly, the
density of platelet serotonin transporter binding, another
marker of depression and suicide, was also correlated with
plasma DHA levels [163]. Thus, many of the serotonergic
alterations associated with low dietary or tissue n-3 PUFAs
are consistent with those observed in depression.8 Depression Research and Treatment
7.4. Eﬀects on the CNS Dopamine Systems. Although the
monoamine theory of depression focuses on serotonin and
norepinephrine [164], the CNS dopamine systems also
appear to play a role in the disease. Decreased dopaminergic
function, particularly of the mesolimbic system, appears
to underlie anhedonic behavior in several animal models
[165–168]. Notably, concentrations of homovanillic acid, a
dopamine metabolite, in cerebrospinal ﬂuid were decreased
in depressed patients and in suicide victims, and were
inversely related to depression scores [169–172]. Depression
is also common in Parkinson’s disease, a neurodegenerative
disease involving the loss of nigrostriatal dopamine neurons
[173, 174]. Accordingly, decreased dopaminergic function
has been hypothesized to contribute to the anhedonia and
motivational deﬁcits associated with depression [175].
Postpartum rats with decreased brain DHA levels exhib-
ited decreased density of D2-like dopamine receptors in
the ventral striatum (nucleus accumbens and olfactory
tubercle) [129]. A trend towards a decrease in D2-like
receptor binding was also observed in virgin females with
decreased brain DHA, suggesting that the decrease in D2-
like receptor binding in this brain region resulted from the
change in brain DHA status, but may be augmented in
the postpartum female. While this observation is consistent
with the proposed hypoactivity of the mesolimbic dopamine
system in depression, a postmortem study of drug-na¨ ıve
patients with major depressive disorder found no diﬀerences
inthedensityofD2 receptorsineithertheventralstriatumor
the caudate nucleus [176]. Nevertheless, decreased densities
of D2-like receptors or D2 receptor mRNA in the nucleus
a c c u m b e n sh a v eb e e nr e p o r t e di ns e v e r a lp u t a t i v er a t
models of depression including chronic mild stress-induced
anhedonia, the socially isolated Flinders sensitive line rat,
and the learned helplessness model [177–179]. Decreased
density of D2-like receptors was also observed in the nucleus
accumbens core of the Wistar-Kyoto rat, another depression
model, though D2-like receptor binding was increased in the
nucleus accumbens shell [180].
Variation in diet and tissue n-3 PUFA content in
other animals models also results in alterations in the
CNS dopamine systems, but these eﬀects vary considerably
depending on the magnitude of the change and the point
in development when the manipulation was made. For
example, in contrast to the eﬀe c t so fal o s so fb r a i nD H Ai n
adult animals, either an increase or no change in the density
of D2 receptors in the nucleus accumbens was observed in
rats with inadequate accumulation of brain DHA during
development, depending on the magnitude of the change
in DHA [181–183]. Thus, the eﬀects of modulation of
brain DHA on the CNS dopamine systems appear to be
more dependent on the speciﬁc manipulation than the other
systems discussed here.
7.5. Eﬀects on Neuroinﬂammation. Neuroinﬂammation is
becoming increasingly recognized as another likely contrib-
utor to the underlying pathology of depression. Of note,
higher circulating levels of several NFκB-regulated inﬂam-
matory mediators including interleukin-1β, interleukin-6,
tumor necrosis factor-α, and interferon-γ have been noted
in depressed patients [184–186]. Depressed patients also
exhibited augmented NFκB and interleukin-6 responses to
psychological stressors [187]. Postmortem studies of brain
from patients with major depression, or who completed
suicide, also indicated increased levels of transmembrane
tumor necrosis factor-α in some cortical regions, as well
as increased expression of genes involved in inﬂammatory
responses [188–191]. Furthermore, studies in postpartum
womenindicatedincreasedlevelsofinﬂammatorymediators
in those with depressive symptoms or who had previously
suﬀered from major depression [192–194].
N-3 PUFAs have a variety of anti-inﬂammatory activities
[195]. DHA is the precursor of neuroprotectin D1, a
mediator formed in brain that inhibits the production of
tumor necrosis factor-α and interferon-γ by activated T cells
[25, 196]. DHA and EPA are also precursors of a variety of
resolvins which control the magnitude and duration of the
inﬂammatory response [197]. In addition, DHA and EPA
inhibit the NFκB-mediated inﬂammation cascade through
actions at the toll-like 4 receptor and PPARs [198, 199].
Consistent with these activities, treatment with either DHA
or EPA reduced expression of a number of inﬂammatory
mediators including tumor necrosis factor-α, interleukin-6,
nitric oxide synthase, and cyclooxygenase 2, and induced
expression of heme oxygenase-1 in cultured BV-2 microglia
[200], indicating potential anti-inﬂammatory mechanisms
through which n-3 PUFAs could exert antidepressant eﬀects.
However, the interaction of low tissue and/or dietary n-3
PUFAs with the postpartum state has not been investigated.
7.6. Eﬀects on Depression-Related Behavior. Although there
is debate regarding the extent to which subhuman species
can experience depression [201], several rodent models have
been proven highly reliable as drug screens for the prediction
ofantidepressanteﬃcacy.Amongthesetests,theforcedswim
testisperhapsthemostvalidated[202]andissometimesalso
used as a putative rodent model of depression. In the test,
rats placed in an inescapable cylindrical tank of cool water
are evaluated for time spent climbing, swimming, ﬂoating
immobile,and,insomestudies,latencytoimmobility.Drugs
that decrease the time spent ﬂoating immobile, or increase
the latency to immobility, are likely to have antidepressant
eﬀects in humans [202, 203].
In the forced swim test, postpartum rats with decreased
brain DHA content exhibited shorter latencies to immobility
than postpartum rats with normal brain DHA levels [49].
This eﬀect was not observed in virgin females with decreased
brain DHA indicating that it represents an interaction of
the decrease in brain DHA content with the postpartum
state. Shorter latency to immobility is also consistent with
an interpretation of a more “depressed” phenotype in the
postpartum rats with decreased brain DHA to the extent
possible within the limitations of the test.
Concordant with these ﬁndings, manipulation of n-3
PUFAs in other rodent models also point to a role for
lower dietary and tissue n-3 PUFA status contributing to
“depressed” behavior in antidepressant drug screens. ForDepression Research and Treatment 9
example, adult rats fed an n-3 PUFA-deﬁcient diet beginning
at weaning, which resulted in brain DHA levels 36% lower
than controls, exhibited more time immobile in the forced
swim test [204]. Conversely, rats or mice that were fed n-
3 PUFA-supplemented diets exhibited less immobility [132,
205–207]. Likewise, adult male mice that were treated with
injections of α-linoleic acid also exhibited less immobility
[131]. Similar eﬀects have also been reported in the tail
suspension test, another rodent antidepressant drug screen
[131, 132].
8. Conclusion
Although a conﬂuence of genetic and environmental factors
may be required to cause depression, an individual factor
(e.g., reduced brain DHA content), may create a state of
vulnerability that contributes to the development of the
disease when the other appropriate factors are present.
The preponderance of the literature indicates that changes
in brain LC-PUFA status, particularly decreased DHA,
are associated with both non-puerperal and postpartum
depression.Furthermore,experimentallyinducedreductions
in brain DHA content result in neurobiological alterations in
rats similar to those observed in depressed humans. These
eﬀects of decreased brain DHA interact with the postpartum
state such that the number of neurobiological alterations
in postpartum rats with decreased brain DHA is greater
than in virgin females with decreased brain DHA, and the
m a g n i t u d eo fs o m eo ft h ea l t e r a t i o n sa p p e a r st ob eg r e a t e r
in the postpartum state. With the low n-3 PUFA content
of the North American diet, there is considerable potential
for individuals to have suboptimal availability of these
fatty acids. Genetic polymorphisms that confer suboptimal
metabolism or utilization of LC-PUFA, or the physiological
demands of pregnancy and lactation, may place certain
individuals at even greater risk. Accordingly, decreased
brain DHA, and perhaps other n-3 PUFAs, represents an
important potential risk factor for depression generally, and
postpartum depression in particular.
Despite this growing body of evidence, the role(s) of LC-
PUFA in the pathogenesis of postpartum depression and
other depressive illnesses remains to be fully elucidated.
In addition to determining speciﬁcally how changes in
brain LC-PUFA composition contribute to the etiology of
depression (e.g., altered membrane properties, actions of
LC-PUFA-derived mediators, etc.), it must be determined
whether n-3 PUFA status contributes to the etiology of
depression in all, or only a subset of, patients (e.g.,
postpartum females). Importantly, the reversibility of the
neurobiological consequences of a pregnancy-associated loss
of brain DHA must be determined. Should these changes
prove to be reversible, this will support the use of n-3 PUFA
supplements in the treatment of postpartum depression. On
the other hand, should the neurobiological consequences of
a pregnancy-associated loss of brain DHA be irreversible,
this will indicate the imperative of preventing the loss of
DHA during pregnancy and lactation through appropriate
nutrition and/or supplementation. Finally, should such
ﬁndings support the viability of preventing postpartum
depression and/or treating existing depressive illness with n-
3LC-PUFAs,theappropriateformulation,optimal dose,and
treatment duration also remain to be determined in well-
designed, adequately powered clinical trials.
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